EX-99.1 2 d902268dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NeuroPace Provides Update on Tariff Status - Minimal expected impact to operations and financial results - - Company to report first quarter 2025 financial results on May 13, 2025 - Mountain View, Calif. - April 14, 2025 - NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its exposure to tariffs that have been implemented. While specific policies and timing of implementation remain fluid, NeuroPace expects minimal impact to its operations and financial results. Specifically, NeuroPace manufactures and sells the vast majority of its devices in the United States and has limited supply chain activities outside the United States for its RNS System. Similarly, the company expects no material impact on gross margin for DIXI Medical SEEG products. As a result, NeuroPace expects minimal impact to its gross margin for fiscal year 2025 and is reiterating its gross margin guidance for 2025. NeuroPace previously announced terminating its SEEG distribution agreement with DIXI Medical effective October 1, 2025 followed by a six-mo…
Open exhibit ↗Current Report · Items 7.01, 9.01 · 8-K
Neuropace, Inc.
NPCENASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 14, 2025, NeuroPace, Inc. (the “Company”) issued a press release announcing that it anticipates minimal impact from the international trade tariffs on its operations and financial results. The Company additionally reaffirmed guidance with respect to its anticipated gross margin for fiscal year 2025.…
Company context
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.